SCHEMBL24726549

SCHEMBL24726549

Cc1ccc(N)c(O)c1F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.38
TSHR P16473 3/20 0.38
CASP1 P29466 2/20 0.38
MAPT P10636 2/20 0.38
KDM4E B2RXH2 1/20 0.38
LMNA P02545 1/20 0.38
GAA P10253 1/20 0.38
PKM P14618 1/20 0.38
TDP1 Q9NUW8 6/20 0.36
CYP3A4 P08684 6/20 0.36
ALOX15 P16050 3/20 0.34
THRB P10828 2/20 0.34
RECQL P46063 1/20 0.34
HIF1A Q16665 1/20 0.34
HSD17B1 P14061 1/20 0.33
HSD17B2 P37059 1/20 0.33
HSD17B10 Q99714 1/20 0.33
PDE10A Q9Y233 1/20 0.33
ESR1 P03372 1/20 0.32
AR P10275 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8013552 0.81 ALDH1A1 (0.40) ALDH1A1TSHRCASP1MAPTKDM4E
SCHEMBL15172767 0.79 ALDH1A1 (0.48) ALDH1A1TSHRCASP1MAPTKDM4E
SCHEMBL1425839 0.77 CYP3A4 (0.40) ALDH1A1TSHRCASP1MAPTTDP1
SCHEMBL1201436 0.77 ALDH1A1 (0.46) ALDH1A1TSHRCASP1MAPTKDM4E
SCHEMBL932188 0.75 ALDH1A1 (0.39) ALDH1A1CYP3A4ALOX15HSD17B1HSD17B2
SCHEMBL2659542 0.75 TRPA1 (0.44) ALDH1A1TSHRCASP1MAPTKDM4E
SCHEMBL405898 0.75 CD44 (0.44) ALDH1A1TSHRCASP1MAPTKDM4E
SCHEMBL14908341 0.75 EP300 (0.41) ALDH1A1TSHRMAPTKDM4EGAA
SCHEMBL2795922 0.75 ALDH1A1 (0.41) ALDH1A1TSHRCASP1MAPTKDM4E
SCHEMBL1009105 0.75 ALDH1A1 (0.38) ALDH1A1TSHRMAPTHSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11518766-B2 Tricyclic compound, preparation method therefor and use thereof SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD. (CN) 2022-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11518766-B2 Tricyclic compound, preparation method therefor and use thereof TFPI, TFPI2, F11 ALDH1A1 3573/4885TSHR 2228/4885CASP1 775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.